{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T23:10:29Z","timestamp":1790809829122,"version":"4.1.0"},"reference-count":154,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:00:00Z","timestamp":1697500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Checkpoint inhibitor therapy has emerged as an effective therapeutic strategy for many types of malignancies, especially in solid tumors. Within the last two decades, numerous monoclonal antibody drugs targeting the CTLA-4 and PD-1\/PD-L1 checkpoint pathways have seen FDA approval. Within hematologic malignancies, Hodgkin Lymphoma has seen the greatest clinical benefits thus far with more recent data showing efficacy in the front-line setting. As our understanding of checkpoint inhibition expands, using these pathways as a therapeutic target has shown some utility in the treatment of other hematologic malignancies as well, primarily in the relapsed\/refractory settings. Checkpoint inhibition also appears to have a role as a synergistic agent to augment clinical responses to other forms of therapy such as hematopoietic stem cell transplant. Moreover, alternative checkpoint molecules that bypass the well-studied CTLA-4 and PD-1\/PD-L1 pathways have emerged as exciting new therapeutic targets. Most excitingly is the use of anti-CD47 blockade in the treatment of high risk MDS and TP-53 mutated AML. Overall, there has been tremendous progress in understanding the benefits of checkpoint inhibition in hematologic malignancies, but further studies are needed in all areas to best utilize these agents. This is a review of the most recent developments and progress in Immune Checkpoint Inhibition in Hematologic Malignancies in the last decade.<\/jats:p>","DOI":"10.3389\/fonc.2023.1288172","type":"journal-article","created":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T06:56:24Z","timestamp":1697525784000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["Checkpoint inhibition in hematologic malignancies"],"prefix":"10.3389","volume":"13","author":[{"given":"Aaron","family":"Tsumura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Levis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Tuscano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"B2","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.4161\/onci.21335","article-title":"Targeting PD-1\/PD-L1 interactions for cancer immunotherapy","volume":"1","author":"Zitvogel","year":"2012","journal-title":"Oncoimmunology"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-843714","article-title":"Mass cytometry of Hodgkin lymphoma reveals a CD4+ regulatory T-cell\u2013rich and exhausted T-effector microenvironment","volume":"132","author":"Cader","year":"2018","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002206","article-title":"The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4\u2013positive T cells that are PD-1\u2013negative","volume":"134","author":"Patel","year":"2019","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand","year":"2016","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II checkMate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2181749","DOI":"10.1080\/16078454.2023.2181749","article-title":"Safety and efficacy of PD-1 and PD-L1 inhibitors in relapsed and refractory Hodgkin\u2019s lymphoma: a systematic review and meta-analysis of 20 prospective studies","volume":"28","author":"Sun","year":"2023","journal-title":"Hematology"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","author":"Kuruvilla","year":"2021","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000480","article-title":"A phase 2 study of nivolumab using a fixed dose of 40\u200amg (Nivo40) in patients with relapsed\/refractory hodgkin lymphoma","volume":"4","author":"Lepik","year":"2020","journal-title":"HemaSphere"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0939-1","article-title":"A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed\/refractory lymphoid Malignancies","volume":"35","author":"Armand","year":"2021","journal-title":"Leukemia"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009178","article-title":"Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results","volume":"138","author":"Advani","year":"2021","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004701","article-title":"A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"136","author":"Bartlett","year":"2020","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30275-1","article-title":"Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial","volume":"7","author":"Cheson","year":"2020","journal-title":"Lancet Haematol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/blood.2019004701","article-title":"Efficacy of nivolumab and AVD in early-stage unfavorable classic hodgkin lymphoma","volume":"6","author":"Br\u00f6ckelmann","year":"2020","journal-title":"JAMA Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02355","article-title":"Nivolumab and doxorubicin, vinblastine, and dacarbazine in early-stage unfavorable hodgkin lymphoma: final analysis of the randomized german hodgkin study group phase II NIVAHL trial","volume":"41","author":"Br\u00f6ckelmann","year":"2023","journal-title":"J Clin Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA4","article-title":"SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL)","volume":"41","author":"Herrera","year":"2023","journal-title":"J Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"5846","DOI":"10.3390\/cancers14235846","article-title":"Anti-PD1 Consolidation in Patients with Hodgkin Lymphoma at High Risk of Relapse after Autologous Stem Cell Transplantation: A Multicenter Real-Life Study","volume":"14","author":"De Filippi","year":"2022","journal-title":"Cancers"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00318-0","article-title":"Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial","volume":"10","author":"Herrera","year":"2023","journal-title":"Lancet Haematol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01421-z","article-title":"Reverted exhaustion phenotype of circulating lymphocytes as immune correlate of anti-PD1 first-line treatment in Hodgkin lymphoma","volume":"36","author":"Garcia-Marquez","year":"2022","journal-title":"Leukemia"},{"key":"B22","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3390\/cancers10110415","article-title":"Profiling immune escape in hodgkin\u2019s and diffuse large B-cell lymphomas using the transcriptome and immunostaining","volume":"10","author":"P\u00e9ricart","year":"2018","journal-title":"Cancers"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00150-7","article-title":"Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study","volume":"2","author":"Keane","year":"2015","journal-title":"Lancet Haematol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-18-0439","article-title":"Immune profiling and quantitative analysis decipher the clinical role of immune-checkpoint expression in the tumor immune microenvironment of DLBCL","volume":"7","author":"Xu-Monette","year":"2019","journal-title":"Cancer Immunol Res"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005872","article-title":"Pembrolizumab plus dinaciclib in patients with hematologic Malignancies: the phase 1b KEYNOTE-155 study","volume":"6","author":"Gregory","year":"2022","journal-title":"Blood Adv"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2136956","article-title":"Pembrolizumab for patients with non-Hodgkin lymphoma: phase 1b KEYNOTE-013 study","volume":"64","author":"Kuruvilla","year":"2023","journal-title":"Leuk Lymphoma"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e1662","DOI":"10.1002\/cnr2.1662","article-title":"Durvalumab as monotherapy and in combination therapy in patients with lymphoma or chronic lymphocytic leukemia: The FUSION NHL 001 trial","volume":"6","author":"Casulo","year":"2023","journal-title":"Cancer Rep Hoboken NJ"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-023-03520-x","article-title":"Immune evasion phenotype is common in Richter transformation diffuse large B-cell lymphoma variant","volume":"482","author":"El Hussein","year":"2023","journal-title":"Virchows Arch Int J Pathol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008790","article-title":"A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL","volume":"7","author":"Jain","year":"2023","journal-title":"Blood Adv"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1182\/blood-2021-151188","article-title":"Atezolizumab combined with immunogenic salvage chemoimmunotherapy (R-gemOx+Atezo) in patients with transformed diffuse large B-cell lymphoma","volume":"138","author":"Herrera","year":"2021","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.649789","article-title":"Relapsed primary central nervous system lymphoma: current advances","volume":"11","author":"Tao","year":"2021","journal-title":"Front Oncol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2021.816098","article-title":"Epstein-barr virus and neurological diseases","volume":"8","author":"Zhang","year":"2022","journal-title":"Front Mol Biosci"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-006-9165-6","article-title":"Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors","volume":"80","author":"Jahnke","year":"2006","journal-title":"J Neurooncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"vdaa018","DOI":"10.1093\/noajnl\/vdaa018","article-title":"Primary CNS lymphoma commonly expresses immune response biomarkers","volume":"2","author":"Ou","year":"2020","journal-title":"Neuro-Oncol Adv"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-673236","article-title":"Targetable genetic features of primary testicular and primary central nervous system lymphomas","volume":"127","author":"Chapuy","year":"2016","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-764209","article-title":"PD-1 blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lymphoma","volume":"129","author":"Nayak","year":"2017","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1182\/blood-2020-138924","article-title":"Nivolumab in primary CNS lymphoma and primary testicular lymphoma with CNS involvement: single center experience","volume":"136","author":"Gavrilenko","year":"2020","journal-title":"Blood"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1742903","article-title":"Pembrolizumab immunotherapy for relapsed CNS Lymphoma","volume":"61","author":"Graber","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1480771","article-title":"Combination immunotherapy as a non-chemotherapy alternative for refractory or recurrent CNS lymphoma","volume":"60","author":"Ambady","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.12.002","article-title":"The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma","volume":"33","author":"Horwitz","year":"2022","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-020-02790-z","article-title":"Clinicopathological features of programmed cell death-1 and programmed cell death-ligand-1 expression in the tumor cells and tumor microenvironment of angioimmunoblastic T cell lymphoma and peripheral T cell lymphoma not otherwise specified","volume":"477","author":"Kim","year":"2020","journal-title":"Virchows Arch"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1881511","article-title":"PD-L1 expression in peripheral T-cell lymphomas is not related to either PD-L1 gene amplification or rearrangements","volume":"62","author":"Manso","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"B44","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1159\/000500974","article-title":"Programmed cell death 1 and programmed cell death ligands in extranodal natural killer\/T cell lymphoma: expression pattern and potential prognostic relevance","volume":"143","author":"Muhamad","year":"2019","journal-title":"Acta Haematol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00277-022-04760-8","article-title":"Prognostic implication of CTLA-4, PD-1, and PD-L1 expression in aggressive adult T-cell leukemia-lymphoma","volume":"101","author":"Onishi","year":"2022","journal-title":"Ann Hematol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004984","article-title":"Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression","volume":"10","author":"Bennani","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2023.2215424","article-title":"Rapid T-cell lymphoma progression associated with immune checkpoint inhibitors","volume":"16","author":"Ohmoto","year":"2023","journal-title":"Expert Rev Hematol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.clml.2019.03.022","article-title":"Phase II study of the PD-1 inhibitor pembrolizumab for the treatment of relapsed or refractory mature T-cell lymphoma","volume":"19","author":"Barta","year":"2019","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B49","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13045-021-01033-1","article-title":"Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)","volume":"14","author":"Shi","year":"2021","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic Malignancy: preliminary results of a phase ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-143252","article-title":"A phase II study of pembrolizumab in combination with romidepsin demonstrates durable responses in relapsed or refractory T-cell lymphoma (TCL)","volume":"136","author":"Iyer","year":"2020","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41392-021-00768-0","article-title":"Sintilimab for relapsed\/refractory extranodal NK\/T cell lymphoma: a multicenter, single-arm, phase 2 trial (ORIENT-4)","volume":"6","author":"Tao","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2833","DOI":"10.1182\/blood-2019-121865","article-title":"Preliminary results from a multicenter, single-arm, phase 2 study of CS1001, an anti-programmed death-ligand 1 (PD-L1) human monoclonal antibody (mAb), in patients (pts) with relapsed or refractory extranodal natural killer\/T cell lymphoma (rr-ENKTL)","volume":"134","author":"Huang","year":"2019","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020007247","article-title":"Avelumab for the treatment of relapsed or refractory extranodal NK\/T-cell lymphoma: an open-label phase 2 study","volume":"136","author":"Kim","year":"2020","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S262039","article-title":"Effective treatment with PD-1 antibody, chidamide, etoposide, and thalidomide (PCET) for relapsed\/refractory natural killer\/T-cell lymphoma: A report of three cases","volume":"13","author":"Du","year":"2020","journal-title":"OncoTargets Ther"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx316","article-title":"Beyond first-line non-anthracycline-based chemotherapy for extranodal NK\/T-cell lymphoma: clinical outcome and current perspectives on salvage therapy for patients after first relapse and progression of disease","volume":"28","author":"Lim","year":"2023","journal-title":"Ann Oncol"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.821918","article-title":"The role of PD-L1 expression in prediction and stratification of recurrent or refractory extranodal natural killer\/T-cell lymphoma","volume":"12","author":"Gao","year":"2022","journal-title":"Front Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.138","article-title":"Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study","volume":"31","author":"Kumar","year":"2017","journal-title":"Leukemia"},{"key":"B59","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/s40001-022-00923-5","article-title":"PD-1 and LAG-3-positive T cells are associated with clinical outcomes of relapsed\/refractory multiple myeloma patients","volume":"27","author":"Chen","year":"2022","journal-title":"Eur J Med Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"5730","DOI":"10.3390\/ijms24065730","article-title":"Inappropriate expression of PD-1 and CTLA-4 checkpoints in myeloma patients is more pronounced at diagnosis: implications for time to progression and response to therapeutic checkpoint inhibitors","volume":"24","author":"Kulikowska de Na\u0142\u0119cz","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-775122","article-title":"Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed\/refractory multiple myeloma","volume":"130","author":"Badros","year":"2023","journal-title":"ScienceDirect"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15946","article-title":"Pembrolizumab combined with lenalidomide and low-dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE-023 study","volume":"186","author":"Mateos","year":"2019","journal-title":"Br J Haematol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30109-7","article-title":"Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial","volume":"6","author":"Usmani","year":"2019","journal-title":"Lancet Haematol"},{"key":"B64","doi-asserted-by":"publisher","first-page":"TPS8052","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS8052","article-title":"CheckMate 602: An open-label, randomized, phase 3 trial of combinations of nivolumab, elotuzumab, pomalidomide and dexamethasone in relapsed\/refractory multiple myeloma","volume":"35","author":"Lonial","year":"2017","journal-title":"J Clin Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30110-3","article-title":"Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial","volume":"6","author":"Mateos","year":"2019","journal-title":"Lancet Haematol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1158105","article-title":"Genetic variants of CTLA4 are associated with clinical outcome of patients with multiple myeloma","volume":"14","author":"Gonzalez-Montes","year":"2023","journal-title":"Front Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.7754\/Clin.Lab.2021.210701","article-title":"Programmed death ligand-1 is frequently expressed in primary acute myeloid leukemia and B-acute lymphoblastic leukemia","volume":"68","author":"Hamdan","year":"2022","journal-title":"Clin Lab"},{"key":"B68","doi-asserted-by":"publisher","first-page":"2823","DOI":"10.3390\/ijms20112823","article-title":"High PD-L1 expression predicts for worse outcome of leukemia patients with concomitant NPM1 and FLT3 mutations","volume":"20","author":"Brodsk\u00e1","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.355","article-title":"Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents","volume":"28","author":"Yang","year":"2014","journal-title":"Leukemia"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0774","article-title":"Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: A non-randomized, open-label, phase 2 study","volume":"9","author":"Daver","year":"2019","journal-title":"Cancer Discovery"},{"key":"B71","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1182\/blood-2019-127345","article-title":"Multi-center phase 2 study of pembroluzimab (Pembro) and azacitidine (AZA) in patients with relapsed\/refractory acute myeloid leukemia (AML) and in newly diagnosed (\u226565 years) AML patients","volume":"134","author":"Gojo","year":"2019","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2148212","article-title":"A randomized phase II\/III study of \u201cnovel therapeutics\u201d versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612","volume":"64","author":"Assouline","year":"2023","journal-title":"Leuk Lymphoma"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005487","article-title":"A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for higher-risk myelodysplastic syndromes","volume":"6","author":"Zeidan","year":"2022","journal-title":"Blood Adv"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017686","article-title":"Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-na\u00efve settings","volume":"141","author":"Garcia","year":"2023","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.21879","article-title":"Increased expression of immune checkpoint programmed cell death protein-1 (PD-1) on T cell subsets of bone marrow aspirates in patients with B-Lymphoblastic leukemia, especially in relapse and at diagnosis","volume":"98","author":"Park","year":"2020","journal-title":"Cytometry B Clin Cytom"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002403","article-title":"Phase 2 study of pembrolizumab for measurable residual disease in adults with acute lymphoblastic leukemia","volume":"4","author":"Cassaday","year":"2020","journal-title":"Blood Adv"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021015341","article-title":"Combining nilotinib and PD-L1 blockade reverses CD4+ T-cell dysfunction and prevents relapse in acute B-cell leukemia","volume":"140","author":"Tracy","year":"2022","journal-title":"Blood"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"B79","doi-asserted-by":"publisher","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1172\/JCI83092","article-title":"Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition","volume":"126","author":"Cherkassky","year":"2016","journal-title":"J Clin Invest"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"key":"B82","doi-asserted-by":"publisher","first-page":"4192","DOI":"10.1182\/blood-2018-99-111523","article-title":"End of phase 1 results from zuma-6: axicabtagene ciloleucel (Axi-cel) in combination with atezolizumab for the treatment of patients with refractory diffuse large B cell lymphoma","volume":"132","author":"Jacobson","year":"2018","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1182\/blood-2018-99-116745","article-title":"Efficacy and toxicity of JCAR014 in combination with durvalumab for the treatment of patients with relapsed\/refractory aggressive B-cell non-hodgkin lymphoma","volume":"132","author":"Hirayama","year":"2018","journal-title":"Blood"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012634","article-title":"Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy","volume":"139","author":"Chong","year":"2022","journal-title":"Blood"},{"key":"B85","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1182\/blood-2018-99-112572","article-title":"Checkpoint inhibitors augment CD19-directed chimeric antigen receptor (CAR) T cell therapy in relapsed B-cell acute lymphoblastic leukemia","volume":"132","author":"Li","year":"2018","journal-title":"Blood"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1061-7","article-title":"Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas","volume":"26","author":"Deng","year":"2020","journal-title":"Nat Med"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.619649","article-title":"Graft versus host disease associated with immune checkpoint inhibitors: A pharmacovigilance study and systematic literature review","volume":"11","author":"Nguyen","year":"2021","journal-title":"Front Pharmacol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-749556","article-title":"Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma","volume":"129","author":"Herbaux","year":"2017","journal-title":"Blood"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-020-02960-4","article-title":"Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study","volume":"112","author":"Ito","year":"2020","journal-title":"Int J Hematol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601202","article-title":"Ipilimumab for patients with relapse after allogeneic transplantation","volume":"375","author":"Davids","year":"2016","journal-title":"N Engl J Med"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004710","article-title":"A multicenter phase 1 study of nivolumab for relapsed hematologic Malignancies after allogeneic transplantation","volume":"135","author":"Davids","year":"2020","journal-title":"Blood"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008403","article-title":"Pembrolizumab for the treatment of disease relapse after allogeneic hematopoietic stem cell transplantation","volume":"7","author":"Godfrey","year":"2023","journal-title":"Blood Adv"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-738385","article-title":"Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed\/refractory lymphoma","volume":"129","author":"Merryman","year":"2023","journal-title":"| Blood | Am Soc Hematol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.02.003","article-title":"Potential survival benefit for patients receiving allogeneic hematopoietic stem cell transplantation after nivolumab therapy for relapse\/refractory hodgkin lymphoma: real-life experience in Spain","volume":"26","author":"Mart\u00ednez","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000134","article-title":"PTCy ameliorates GVHD by restoring regulatory and effector T-cell homeostasis in recipients with PD-1 blockade","volume":"3","author":"Ikegawa","year":"2019","journal-title":"Blood Adv"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32796","article-title":"Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML\/MDS who are treated with checkpoint inhibitors","volume":"126","author":"Oran","year":"2020","journal-title":"Cancer"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1021.e1","DOI":"10.1016\/j.jtct.2021.08.022","article-title":"Safety and efficacy of pembrolizumab prior to allogeneic stem cell transplantation for acute myelogenous leukemia","volume":"27","author":"Tschernia","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019001336","article-title":"Checkpoint inhibition before haploidentical transplantation with posttransplant cyclophosphamide in Hodgkin lymphoma","volume":"4","author":"De Philippis","year":"2020","journal-title":"Blood Adv"},{"key":"B99","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1016\/j.immuni.2022.03.013","article-title":"Binding of LAG-3 to stable peptide-MHC class II limits T cell function and suppresses autoimmunity and anti-cancer immunity","volume":"55","author":"Maruhashi","year":"2022","journal-title":"Immunity"},{"key":"B100","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.cell.2018.11.010","article-title":"Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG3","volume":"176","author":"Wang","year":"2019","journal-title":"Cell"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.18251","article-title":"Expression of LAG-3 defines exhaustion of intratumoral PD-1+ T cells and correlates with poor outcome in follicular lymphoma","volume":"8","author":"Yang","year":"2017","journal-title":"Oncotarget"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.148965","article-title":"Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia","volume":"102","author":"Shapiro","year":"2017","journal-title":"Haematologica"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6268","article-title":"A unique expression pattern of LAG3 distinct from that of other immune checkpoints in diffuse large B-cell lymphoma","volume":"12","author":"Lee","year":"2023","journal-title":"Cancer Med"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023009813","article-title":"Diffuse large B-cell lymphomas have spatially-defined tumor-immune microenvironments revealed by high-parameter imaging","volume":"7","author":"Wright","year":"2023","journal-title":"Blood Adv"},{"key":"B105","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.3390\/cancers13092112","article-title":"LAG-3 blockade with relatlimab (BMS-986016) restores anti-leukemic responses in chronic lymphocytic leukemia","volume":"13","author":"Sordo-Bahamonde","year":"2021","journal-title":"Cancers"},{"key":"B106","unstructured":"Study Record | Beta ClinicalTrials.gov2023"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1038\/ni1271","article-title":"The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity","volume":"6","author":"Zhu","year":"2005","journal-title":"Nat Immunol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5549","article-title":"Upregulation of Tim-3 is associated with poor prognosis in acute myeloid leukemia","volume":"12","author":"Wu","year":"2023","journal-title":"Cancer Med"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.753677","article-title":"TIM-3 in Leukemia; immune response and beyond","volume":"11","author":"Rezaei","year":"2021","journal-title":"Front Oncol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/j.stem.2010.11.014","article-title":"TIM-3 is a promising target to selectively kill acute myeloid leukemia stem cells","volume":"7","author":"Kikushige","year":"2010","journal-title":"Cell Stem Cell"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-310425","article-title":"Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia","volume":"117","author":"Zhou","year":"2011","journal-title":"Blood"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v10.i32.11804","article-title":"T-cell immunoglobulin mucin molecule-3, transformation growth factor \u03b2, and chemokine-12 and the prognostic status of diffuse large B-cell lymphoma","volume":"10","author":"Wu","year":"2022","journal-title":"World J Clin cases"},{"key":"B113","doi-asserted-by":"publisher","first-page":"4526","DOI":"10.3390\/ijms24054526","article-title":"Overexpression of potential markers of regulatory and exhausted CD8+ T cells in the peripheral blood mononuclear cells of patients with B-acute lymphoblastic leukemia","volume":"24","author":"Naghavi Alhosseini","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008854","article-title":"Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia","volume":"7","author":"Irani","year":"2023","journal-title":"Blood Adv"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-1237","article-title":"STIMULUS-MDS2 design and rationale: a phase III trial with the anti-TIM-3 sabatolimab (MBG453) + azacitidine in higher risk MDS and CMML-2","volume":"19","author":"Zeidan","year":"2023","journal-title":"Future Oncol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"ltac019","DOI":"10.1093\/immadv\/ltac019","article-title":"Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor","volume":"2","author":"Schwartz","year":"2022","journal-title":"Immunother Adv"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-158612","article-title":"Primary results of stimulus-MDS1: A randomized, double-blind, placebo-controlled phase II study of TIM-3 inhibition with sabatolimab added to hypomethylating agents (HMAs) in adult patients with higher-risk myelodysplastic syndromes (MDS)","volume":"140","author":"Zeidan","year":"2022","journal-title":"Blood"},{"key":"B118","doi-asserted-by":"publisher","first-page":"115583","DOI":"10.1016\/j.bcp.2023.115583","article-title":"Identification of a novel small-molecule inhibitor targeting TIM-3 for cancer immunotherapy","volume":"212","author":"Wu","year":"2023","journal-title":"Biochem Pharmacol"},{"key":"B119","unstructured":"Study record | Beta clinicalTrials.gov2023"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.699895","article-title":"TIGIT, the next step towards successful combination immune checkpoint therapy in cancer","volume":"12","author":"Ge","year":"2021","journal-title":"Front Immunol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1091782","article-title":"TIGIT: A promising target to overcome the barrier of immunotherapy in hematological Malignancies","volume":"12","author":"Jin","year":"2022","journal-title":"Front Oncol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003081","article-title":"Cutting edge: TIGIT has T cell-intrinsic inhibitory functions","volume":"186","author":"Joller","year":"2011","journal-title":"J Immunol Baltim Md 1950"},{"key":"B123","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.imbio.2015.08.003","article-title":"TIGIT negatively regulates inflammation by altering macrophage phenotype","volume":"221","author":"Chen","year":"2016","journal-title":"Immunobiology"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1136\/gut.49.2.236","article-title":"Overexpression of the CD155 gene in human colorectal carcinoma","volume":"49","author":"Masson","year":"2001","journal-title":"Gut"},{"key":"B125","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/1476-4598-12-60","article-title":"Nectin-2 is a potential target for antibody therapy of breast and ovarian cancers","volume":"12","author":"Oshima","year":"2013","journal-title":"Mol Cancer"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2246-5","article-title":"TIGIT: a novel immunotherapy target moving from bench to bedside","volume":"67","author":"Solomon","year":"2018","journal-title":"Cancer Immunol Immunother CII"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-17-2337","article-title":"T cells expressing checkpoint receptor TIGIT are enriched in follicular lymphoma tumors and characterized by reversible suppression of T-cell receptor signaling","volume":"24","author":"Josefsson","year":"2018","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1371399","article-title":"TIGIT expressing CD4+T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia","volume":"7","author":"Catakovic","year":"2017","journal-title":"Oncoimmunology"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.01.013","article-title":"Monitoring TIGIT\/DNAM-1 and PVR\/PVRL2 immune checkpoint expression levels in allogeneic stem cell transplantation for acute myeloid leukemia","volume":"25","author":"Hattori","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-01-825240","article-title":"Myeloma escape after stem cell transplantation is a consequence of T-cell exhaustion and is prevented by TIGIT blockade","volume":"132","author":"Minnie","year":"2018","journal-title":"Blood"},{"key":"B131","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12943-022-01655-0","article-title":"TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma","volume":"21","author":"Jiang","year":"2022","journal-title":"Mol Cancer"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.05.046","article-title":"CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis","volume":"138","author":"Jaiswal","year":"2009","journal-title":"Cell"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-338020","article-title":"Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy","volume":"118","author":"Chao","year":"2011","journal-title":"Blood"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.141","article-title":"Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells","volume":"26","author":"Kim","year":"2012","journal-title":"Leukemia"},{"key":"B135","doi-asserted-by":"publisher","first-page":"110255","DOI":"10.1016\/j.intimp.2023.110255","article-title":"The CD47-SIRP\u03b1 axis is a promising target for cancer immunotherapies","volume":"120","author":"Hao","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2009.05.045","article-title":"CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells","volume":"138","author":"Majeti","year":"2009","journal-title":"Cell"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by hu5F9-G4 and rituximab in non-hodgkin\u2019s lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N Engl J Med"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.7507","article-title":"Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase Ib results","volume":"38","author":"Sallman","year":"2020","journal-title":"J Clin Oncol"},{"key":"B139","doi-asserted-by":"publisher","first-page":"4089","DOI":"10.1182\/blood-2019-125310","article-title":"Anti-CD47 antibody, CC-90002, in combination with rituximab in subjects with relapsed and\/or refractory non-hodgkin lymphoma (R\/R NHL)","volume":"134","author":"Abrisqueta","year":"2019","journal-title":"Blood"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-021-04734-2","article-title":"Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed\/refractory acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"101","author":"Zeidan","year":"2022","journal-title":"Ann Hematol"},{"key":"B141","doi-asserted-by":"publisher","first-page":"4063","DOI":"10.1182\/blood-2019-122793","article-title":"TJC4, a differentiated anti-CD47 antibody with novel epitope and RBC sparing properties","volume":"134","author":"Meng","year":"2019","journal-title":"Blood"},{"key":"B142","doi-asserted-by":"publisher","first-page":"3542","DOI":"10.1182\/blood-2021-150606","article-title":"Lemzoparlimab, a differentiated anti-CD47 antibody in combination with rituximab in relapsed and refractory non-hodgkin\u2019s lymphoma: initial clinical results","volume":"138","author":"Mehta","year":"2021","journal-title":"Blood"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-134391","article-title":"A phase I\/IIa study of lemzoparlimab, a monoclonal antibody targeting CD47, in patients with relapsed and\/or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): initial phase I results","volume":"136","author":"Qi","year":"2020","journal-title":"Blood"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0792-779","article-title":"By\u2013passing immunization: building high affinity human antibodies by chain shuffling","volume":"10","author":"Marks","year":"1992","journal-title":"Bio\/Technology"},{"key":"B145","doi-asserted-by":"publisher","first-page":"2448","DOI":"10.1182\/blood-2021-154490","article-title":"Updates from ongoing, first-in-human phase 1 dose escalation and expansion study of TTI-621, a novel biologic targeting CD47, in patients with relapsed or refractory hematologic Malignancies","volume":"138","author":"Horwitz","year":"2021","journal-title":"Blood"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00271-4","article-title":"Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or S\u00e9zary syndrome: a multicentre, phase 1 study","volume":"8","author":"Querfeld","year":"2021","journal-title":"Lancet Haematol"},{"key":"B147","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1182\/blood-2021-153683","article-title":"CD47-blocker TTI-622 shows single-agent activity in patients with advanced relapsed or refractory lymphoma: update from the ongoing first-in-human dose escalation study","volume":"138","author":"Patel","year":"2021","journal-title":"Blood"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-135941","article-title":"ALX148, a CD47 blocker, in combination with rituximab in patients with non-hodgkin lymphoma","volume":"136","author":"Kim","year":"2020","journal-title":"Blood"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.2550","article-title":"Preliminary results of a first-in-human phase I dtudy of IMM01, SIRP\u03b1 Fc protein in patients with relapsed or refractory lymphoma","volume":"39","author":"Sun","year":"2021","journal-title":"J Clin Oncol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01805-9","article-title":"IMM0306, a fusion protein of CD20 mAb with the CD47 binding domain of SIRP\u03b1, exerts excellent cancer killing efficacy by activating both macrophages and NK cells via blockade of CD47-SIRP\u03b1 interaction and Fc\u0263R engagement by simultaneously binding to CD47 and CD20 of B cells","volume":"37","author":"Yu","year":"2023","journal-title":"Leukemia"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-1095","article-title":"Preclinical development of a bispecific antibody that safely and effectively targets CD19 and CD47 for the treatment of B cell lymphoma and leukemia","volume":"17","author":"Buatois","year":"2018","journal-title":"Mol Cancer Ther"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-438028","article-title":"A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed\/refractory multiple myeloma","volume":"120","author":"Benson","year":"2012","journal-title":"Blood"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-437558","article-title":"A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission","volume":"120","author":"Vey","year":"2012","journal-title":"Blood"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.2174\/1568009623666230523155808","article-title":"The influence of KIR gene polymorphisms and KIR-ligand binding on outcomes in hematologic Malignancies following haploidentical stem cell transplantation: A comprehensive review","volume":"23","author":"Bakhtiari","year":"2023","journal-title":"Curr Cancer Drug Targets"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1288172\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T06:56:28Z","timestamp":1697525788000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1288172\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,17]]},"references-count":154,"alternative-id":["10.3389\/fonc.2023.1288172"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1288172","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,17]]},"article-number":"1288172"}}